A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Inclusion Criteria:
Exclusion Criteria:
medinfo@amgen.com866-572-6436
Birmingham, Alabama 35205, United States
Winter Park, Florida 32789, United States
Arlington Heights, Illinois 60005, United States
Park Ridge, Illinois 66068, United States
Midland, Michigan 48670, United States
Bridgeton, Missouri 63044, United States
Flemington, New Jersey 08822, United States
Secaucus, New Jersey 07094, United States
Dallas, Texas 75226, United States
Newport News, Virginia 23606, United States
Sippy Downs, Queensland 4556, Australia
North York, Ontario M6B 3H7, Canada
Montreal, Quebec H2W 1T8, Canada
Montreal, Quebec H4A 3J1, Canada